In the subgroup analysis, c-MET was correlated to OS in the subgroups with patients older than 65 years at diagnosis, PR low-expressing tumors, luminal B-like HER2− breast cancer subtype, invasive ductal tumors, and histological grade II tumors (see Additional file 8). This evidence concerns the gene MET and breast cancer.